Castle Biosciences Receives Assay Approval From The New York State Department Of Health For Its TissueCypher Barrett's Esophagus Test

Benzinga · Jan 6 20:04

TissueCypher is the first AI-driven precision medicine test designed to predict a patient's individual risk of progression from Barrett's esophagus (BE) to esophageal cancer.

With this approval, all of the tests in Castle's dermatology, gastroenterology and ophthalmology portfolios, as well as its clinical laboratories in Phoenix and Pittsburgh, are now approved by the state of New York.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Castle Biosciences Receives Assay Approval From The New York State Department Of Health For Its TissueCypher Barrett's Esophagus Test

Risk Disclaimer